N-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐

N-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐

中文名称N-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐
中文同义词N-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐;非肽ANG-(1-7)激动剂(AVE 0991 SODIUM SALT);化合物 T14354
英文名称AVE 0991 (sodiuM salt)
英文同义词AVE 0991 (sodiuM salt);AVE0991.Na salt;N-[(Ethylamino)carbonyl]-3-[4-[(5-formyl-4-methoxy-2-phenyl-1H-imidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)-2-thiophenesulfonamide monosodium salt;ethylcarbamoyl-[3-[4-[(5-formyl-4-methoxy-2-phenylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylazanide;AVE 0991 Sodium
CAS号306288-04-0
分子式C29H33N4NaO5S2
分子量604.72
EINECS号
相关类别细胞生物学试剂
Mol文件306288-04-0.mol
结构式N-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐 结构式

N-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐 性质

储存条件Store at -20°C
溶解度溶于二甲基亚砜
形态粉末

N-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐 用途与合成方法

AVE 0991 sodium salt 是一种有效的非肽Ang-(1-7) 受体 Mas 激动剂。AVE 0991 sodium salt 与 [125I]-Ang-(1-7) 竞争性地结合到牛主动脉内皮细胞膜,IC50 为 21 nM。

IC50: 21±35 nM (Ang-(1-7) receptor)

AVE 0991 is a nonpeptide compound that evokes effects similar to Ang-(1-7) on the endothelium. AVE 0991 and unlabeled Ang-(1-7) compete for high-affinity binding of [ 125 I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC 50 s of 21±35 and 220±280 nM, respectively. Peak concentrations of NO and O 2 - release by AVE 0991 sodium salt and Ang-(1-7) (both 10 μM) are not significantly different (NO: 295±20 and 270±25 nM; O 2 - : 18±2 and 20±4 nM). However, the released amount of bioactive NO is ≈5 times higher for AVE 0991 in comparison to Ang-(1-7).

AVE 0991 (0.58 nmol/g) produces a significant decrease of water diuresis in WT mice compared with vehicle-treated animals (0.06±0.03 mL versus 0.27±0.05; n=9 for each group; P<0.01). The antidiuretic effect of AVE 0991 (AVE) is associated with an increase in urine osmolality (1669±231.0 mOsm/KgH 2 O versus 681.1±165.8 mOsm/KgH 2 O in vehicle-treated mice; P<0.01). The genetic deletion of Mas abolishes the antidiuretic effect of AVE 0991 during water loading (0.37±0.10 mL [n=9] versus 0.27±0.03 mL [n=11] in AVE 0991-treated mice). As observed with C57BL/6 mice, administration of AVE 0991 (0.58 nmol/g) in water-loaded Swiss mice also produces a significant decrease of the urinary volume compared with vehicle-treated animals (0.13±0.05 mL [n=16] versus 0.51±0.04 mL [n=40]; P<0.01). One week of treatment with AVE-0991 produces a significant decrease in perfusion pressure (56.55±0.86 vs. 68.73±0.69 mmHg in vehicle-treated rats) and an increase in systolic tension (11.40±0.05 vs. 9.84±0.15 g in vehicle-treated rats), rate of tension rise (+dT/dt; 184.30±0.50 vs. 155.20±1.97 g/s in vehicle-treated rats), rate of tension fall (−dT/dt; 179.60±1.39 vs. 150.80±2.42 g/s in vehicle-treated rats). A slight increase in heart rate (HR) is also observed (220.40±0.71 vs. 214.20±0.74 beats/min in vehicle-treated rats.

安全信息

MSDS信息

更新日期产品编号产品名称CAS号包装价格
2024/01/25HY-15778AN-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐
AVE 0991 sodium salt
306288-04-02mg1550元
2024/01/25HY-15778AN-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐
AVE 0991 sodium salt
306288-04-05mg2325元

N-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐 上下游产品信息

"N-[(乙基氨基)羰基]-3-[4-[(5-甲酰基-4-甲氧基-2-苯基-1H-咪唑-1-基)甲基]苯基]-5-异丁基-2-噻吩磺酰胺单钠盐"相关产品信息
N-乙基乙二胺 N-乙基间甲苯胺 N-乙基吡咯烷酮 N-羟乙基-2-吡咯烷酮
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 | 评选活动 | HS海关编码 | MSDS查询 | 化工站点

Copyright © 2016-2023 ChemicalBook 版权所有  京ICP备07040585号  京公海网安备11010802032676号  

互联网增值电信业务经营许可证:京ICP证150597号  互联网药品信息服务资格证编号(京)-非经营性-2015-0073  信息系统安全等级保护备案证明(三级)  营业执照公示

根据相关法律法规和本站规定,单位或个人购买相关危险物品应取得有效的资质、资格条件。
参考《应急管理部等多部门关于加强互联网销售危险化学品安全管理的通知 (应急〔2022〕119号)》《互联网危险物品信息发布管理规定》